In Section C, contributors will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until illness progression or even the participants are unable to tolerate the study drugs. and after that advertise H3K27Ac at this region. Chromatin hyperacetylation could boost https://clinical-effectiveness-of79023.techionblog.com/31947752/5-essential-elements-for-abbv-744-drug-development-progress-and-timeline